Mark Kirschbaum's most recent trade in Cyclacel Pharmaceuticals Inc was a trade of 70,200 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 30, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cyclacel Pharmaceuticals Inc | Mark Kirschbaum | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 70,200 | 70,200 | - | - | Stock Option (right to buy) | |
| Cyclacel Pharmaceuticals Inc | Mark Kirschbaum | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 31,200 | 31,200 (0%) | 0% | 0 | Common Stock | |
| Cyclacel Pharmaceuticals Inc | Mark Kirschbaum | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2021 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Cyclacel Pharmaceuticals Inc | Mark Kirschbaum | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Oct 2020 | 120,000 | 120,000 | - | - | Stock Option (right to buy) |